The European Medicine Agency (EMA) has issued a positive opinion to support the approval of Veyvondi (vonicog alfa) to treat haemorrhages in children with von Willebrand disease (VWD).  Veyvondi has been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The CHMP issued the opinion for treatment of VWD when desmopressin (DDAVP) treatment alone […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!